Rising Liver Cancer Prevalence Fuels Expansion Of Non-Alcoholic Steatohepatitis Biomarkers Market: A Leading Driver Behind Non-Alcoholic Steatohepatitis Biomarkers Market Expansion in 2025

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Will the Non-Alcoholic Steatohepatitis Biomarkers Industry Market Size Be by 2025?
The market for biomarkers in non-alcoholic steatohepatitis has experienced significant expansion in the past few years. The market, which was valued at $1.36 billion in 2024, is projected to increase to $1.7 billion in 2025, with a compound annual growth rate (CAGR) of 24.8%. The historical growth is associated with factors such as the prevalence of diabetes and metabolic syndrome, the implementation of awareness and screening initiatives, limitations in liver biopsy procedures, regulatory supports, the shift towards individualized healthcare, and clinical trials focused on NASH.

What's the Long-Term Growth Forecast for the Non-Alcoholic Steatohepatitis Biomarkers Market Size Through 2029?
Expectations suggest that the non-alcoholic steatohepatitis biomarkers market will undergo significant growth in the coming years, with a projected market size of $3.86 billion by 2029 and a compound annual growth rate of 22.8%. This predicted growth in the forecasting period is due to a combination of factors including the introduction of new therapies, the broadening scope of precision medicine approaches, patient advocacy efforts, combined multi-omics data utilization, and intensified patient engagement. Among key trends anticipated during the forecast period are telemedicine and remote patient monitoring, the development of innovative diagnostic platforms, worldwide research collaborations, advancements in biomarker discovery technology, the incorporation of artificial intelligence (AI), and the usage of imaging biomarkers.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

What Are the Key Growth Drivers Fueling the Non-Alcoholic Steatohepatitis Biomarkers Market Expansion?
The non-alcoholic steatohepatitis biomarkers market is forecasted to experience a boost due to the increasing incidences of liver cancer. Malignant tumors that grow within the liver itself mark primary liver cancer, whilst secondary or metastatic liver cancer is caused by the spread of the cancer to the liver from other parts of the body. Biomarkers for Non-alcoholic steatohepatitis (NASH) play a significant role in diagnosing liver cancer early, monitoring the progression of the disease, assessing the response to treatment, as well as providing prognostic information, thus reducing the necessity for aggressive procedures. The World Cancer Research Fund, a not-for-profit organization based in the UK, reported that there were nearly 866,136 new liver cancer cases worldwide in 2022, positioning it as the 6th most common type of cancer. Consequently, the increasing prevalence of liver cancer is a key driver for the advancement of the non-alcoholic steatohepatitis biomarkers market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp

What Are the Key Trends Driving Non-Alcoholic Steatohepatitis Biomarkers Market Growth?
A significant trend in the non-alcoholic steatohepatitis biomarkers market is the adoption of technological innovation. To secure their market positions, key companies in the sector are focusing on the creation of inventive solutions. For example, in October 2022, GENFIT, a late-phase biopharmaceutical establishment based in France, and LabCorp, a life sciences firm from the United States, established an exclusive licensing agreement for five years regarding the use of GENFIT's NIS4 technology. This technology, primarily designed to identify non-alcoholic steatohepatitis (NASH) cases and those with advanced fibrosis (F > 2), also known as NASH-at-risk, is a novel, multi-biomarker algorithm. As part of their contract, LabCorp agreed to develop and market a blood-based molecular diagnostic examination using NIS4 technology in Canada and the United States, ensuring wide-ranging access for medical professionals.

How Is the Non-Alcoholic Steatohepatitis Biomarkers Market Segmented?
The non-alcoholic steatohepatitis biomarkers market covered in this report is segmented -

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types
2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses

Subsegments:
1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index
2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin
3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)
4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)
5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9002&type=smp

Which Companies Are Leading the Charge in Non-Alcoholic Steatohepatitis Biomarkers Market Innovation?
Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine

Which Regions Are Leading the Global Non-Alcoholic Steatohepatitis Biomarkers Market in Revenue?
North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9002

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.